A5072476615- Advanced Breast Cancer Therapies
- Click Chemistry and Applications
- HER2/EGFR in Cancer Research
- Synthesis and biological activity
- Global Cancer Incidence and Screening
- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Breast Implant and Reconstruction
- Colorectal Cancer Screening and Detection
- Lung Cancer Treatments and Mutations
- Lymphatic System and Diseases
- Cancer-related Molecular Pathways
- Advances in Oncology and Radiotherapy
- Economic and Financial Impacts of Cancer
- Reconstructive Surgery and Microvascular Techniques
- Cervical Cancer and HPV Research
- Gallbladder and Bile Duct Disorders
- Nutrition, Genetics, and Disease
- Aortic Disease and Treatment Approaches
- Thyroid Cancer Diagnosis and Treatment
- Advanced Biosensing Techniques and Applications
- Liver Disease and Transplantation
- Multiple and Secondary Primary Cancers
Cleveland Clinic
1998-2024
Cleveland Clinic Lerner College of Medicine
2023
Case Western Reserve University
2023
Texas Oncology
2021
Fairview Southdale Hospital
2001
Abstract Purpose: Despite extensive genomic and transcriptomic profiling, it remains unknown how signaling pathways are differentially activated tumors sensitized to certain perturbations. Here, we aim characterize AKT activity its association with other or IHC-based PI3K/AKT pathway biomarkers as well the clinical of ipatasertib (AKT inhibitor) in FAIRLANE trial. Experimental Design: In FAIRLANE, 151 patients early triple-negative breast cancer (TNBC) were randomized 1:1 receive paclitaxel...
Abstract Purpose of review Alternatives to surgical management breast disease is desired by patients wishing avoid an operation or those who are not a candidate for surgery. The role cryoablation treatment benign and malignant tumors reviewed determine optimal candidacy. Recent findings Cryoablation safe, effective, well tolerated patients. being increasingly utilized treat subset with primary cancer most effective when treating small lesions without extensive intraductal component....
e12612 Background: Triple-negative breast cancer (TNBC) constitutes approximately 15% of all cancers and predominantly affects younger women with a disproportionate impact on Black Hispanic ethnicities. Historically, neoadjuvant therapy centered around chemotherapy alone. However, the KEYNOTE 522 trial has demonstrated improved outcomes incorporation PD-1 inhibitor Pembrolizumab alongside chemotherapy. Methods: A retrospective cohort analysis 106 patients treated regimen within Cleveland...
Both the American Cancer Society and National Comprehensive Network recommend annual clinical breast examination (CBE) along with screening mammogram (SM) for patients starting at 40 years of age. However, a palpable mass should have diagnostic (DM) during workup. Review our institution demonstrated that 11% newly diagnosed cancer self-identified had SM instead DM. This led us to question whether primary care physicians (PCP) perform CBE prior ordering mammography. As part routine preimaging...
Minimizing margin re-excision optimizes patient care by providing appropriate oncologic resection and reducing costs. This study aims to assess positivity rate in two groups: shave based on gross specimen (control group, CG) vs intraoperative imaging (radiographic RG). A total of 182 patients who underwent lumpectomy for stage O-III breast cancer at a single institution from January 2013 2014 were evaluated. There was statistically significant decrease with mammography but not ultrasound....
17033 Background: The role of mammography (MG) but not breast self-exam (BSE) and clinical exam (CBE) in cancer detection survival is well documented. This study compares the different methods subsequent rates, analyzing differences even within same stage disease. Methods: Retrospective review 1,259 patients was done using hospital Tumor Registry data. Only with I, IIA IIB are included were diagnosed between April 1992 to December 2005 follow up ranging from June 1993 August 2006. studied...
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers Response the FAIRLANE Trial Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers Response the FAIRLANE Trial Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers Response the FAIRLANE Trial Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers Response the FAIRLANE Trial Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers Response the FAIRLANE Trial Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers Response the FAIRLANE Trial Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers Response the FAIRLANE Trial Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer